Ask AI
ProCE Banner Activity

New Advances in Second-line Treatment and Beyond

Slideset

Download this slideset from a recent symposium with expert perspectives and guidance on treatment for relapsed/refractory, as well as a discussion of novel emerging treatment strategies.

Released: May 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, and Lilly.

AstraZeneca

BeOne Medicines

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This educational activity is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for individuals with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Support patient engagement in care for CLL/SLL through effective shared decision-making and communication strategies

  • Compare the mechanisms of action and clinical rationales for novel targeted therapies that are approved vs under investigation for management of CLL/SLL

  • Recommend individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with CLL/SLL in alignment with patient preferences, clinical evidence, and expert recommendations

  • Assess the clinical implications of emerging efficacy and safety data for novel targeted and cellular therapies on treatment sequencing in CLL/SLL

  • Apply best practices for biomarker testing before treatment initiation and at disease progression to guide optimal therapy selection and sequencing in patients with CLL/SLL